A study was conducted in Alberta, Canada to examine the effectiveness of sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in adults with diabetes and non-severe albuminuria. The study found that SGLT2i may prevent eGFR (estimated glomerular filtration rate) decline and reduce the risk of adverse kidney events in adults with diabetes, regardless of baseline albuminuria status. SGLT2i use was associated with a lower annual eGFR loss and fewer adverse kidney events, but was not associated with all-cause mortality.
